NCT04355533

Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19

Seroprevalence and Antibody Profiling Against SARS-CoV2 in Children and Their Parents

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,056 (actual)
• Sponsor: Assistance Publique - Hôpitaux de Paris · Academic / Other
• Sex: All
• Age: 7 Days
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to provide data on the proportion of seroconverted children and their immune status. It will also provide insight into the number of children currently infected at each time point including healthy carriers. Investigators will provide similar data on their parents in an ancillary study.

Detailed description

The fraction of undiagnosed but likely to transmit the virus is a critical epidemiological characteristic that modulates the epidemic potential of SARS-CoV2. To adapt the epidemy control, it is essential to study the immunoprotection of the general population. A crucial question is the study of pauci or asymptomatic subjects, and in particular children who make mild forms, because they could act as a real reservoir for the spread of the virus. The serological study is essential in this context. The serologic test Abbott will be used to study immunoprevalence. Institut Pasteur has validated test using neutralizing Ab. CEA will used a antibodies and antigen test.

Conditions

• COVID-19 Infection

Interventions

Type	Name	Description
BIOLOGICAL	serology test	volume according to child weight
BIOLOGICAL	nasopharyngeal swab	nasopharyngeal swab for PCR
BIOLOGICAL	rectal swab	rectal swab for PCR
BIOLOGICAL	saliva sample	for biocollection

Timeline

• Start date: 2020-07-29
• Primary completion: 2022-05-20
• Completion: 2022-05-24
• First posted: 2020-04-21
• Last updated: 2026-01-06

Locations

1 site across 1 country: France